|1.||Bagherzadeh, A: 1 article (02/2010)|
|2.||Tickner, M: 1 article (02/2010)|
|3.||Zachary, I: 1 article (02/2010)|
|4.||Jia, H: 1 article (02/2010)|
|5.||Selwood, D: 1 article (02/2010)|
|6.||Cheng, L: 1 article (02/2010)|
|7.||Harris, Richard: 1 article (05/2006)|
|8.||Esposito, Diego: 1 article (05/2006)|
|9.||Driscoll, Paul C: 1 article (05/2006)|
|10.||Selwood, David L: 1 article (05/2006)|
02/02/2010 - "In this study we used a specific antagonist of VEGF binding to the NRP1 b1 domain, EG3287, to investigate the functional roles of NRP1 in human carcinoma cell lines, non-small-cell lung A549, kidney ACHN, and prostate DU145 cells expressing NRP1, and the underlying mechanisms involved. "
02/02/2010 - "EG3287 potently displaced the specific binding of VEGF to NRP1 in carcinoma cell lines and significantly inhibited the migration of A549 and ACHN cells. "
05/12/2006 - "The bicyclic peptide, EG3287, potently (K(i) 1.2 microM) and effectively (>95% inhibition at 100 microM) inhibited VEGF-A165 binding to porcine aortic endothelial cells expressing NP-1 (PAE/NP-1) and breast carcinoma cells expressing only NP-1 receptors for VEGF-A, but had no effect on binding to PAE/KDR or PAE/Flt-1. Molecular dynamics calculations, a nuclear magnetic resonance structure of EG3287, and determination of stability in media, indicated that it constitutes a stable subdomain very similar to the corresponding region of native VEGF-A165. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)